EUDA Health Holdings Limited — Form 6-K Summary
Reporting period: Form 6-K furnished for April 2024, dated April 30, 2024. EUDA is a foreign private issuer filing annual reports on Form 20-F.
Business Context and Material Event
In connection with EUDA’s November 2022 business combination, the Company issued Loeb & Loeb LLP a $300,000 promissory note and 60,000 restricted ordinary shares, valued at an assumed $5.00 per share. The note was due November 17, 2023 but remained unpaid.
On April 25, 2024, EUDA and Loeb entered into a Fee Settlement Agreement. EUDA agreed to repay the $300,000 note in three equal cash installments:
- $100,000 due on or before April 30, 2024;
- $100,000 due on or before May 31, 2024; and
- $100,000 due on or before June 30, 2024.
Loeb is entitled to retain the 60,000 shares, and proceeds from any sale of the shares will not be applied to the note repayment.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt balances beyond the $300,000 Loeb note, liquidity measures, or other financial statement data.
The settlement creates a total cash obligation of $300,000, payable in three installments through June 30, 2024. The filing does not state whether the first installment was paid by April 30, 2024 or describe the source of funds.
Changes Versus the Prior Comparable Period
- The previously overdue $300,000 note was formally restructured into three scheduled cash installments.
- Under the original arrangement, repayment by the November 17, 2023 due date would have required Loeb to return the 60,000 shares for cancellation. Under the settlement, Loeb retains the shares regardless of repayment.
Outlook, Risks, and Unusual Items
The filing provides no operating guidance or broader business outlook.
- Cash payment risk: EUDA must fund three installments by April 30, May 31, and June 30, 2024.
- Share retention and dilution: Loeb’s retention of the 60,000 shares means the shares will not be cancelled, and the filing does not describe any effect on future dilution or trading activity.
- Default or enforcement risk: The filing does not specify remedies, penalties, or consequences if EUDA fails to make an installment.
- Related documentation: The original Agreement and the April 25, 2024 Settlement Agreement were filed as Exhibits 10.1 and 10.2. The filing states that its summary is qualified in its entirety by those documents.
Key Facts for Investors to Verify
- Whether the $100,000 installment due on or before April 30, 2024 was paid.
- EUDA’s available cash and liquidity relative to the remaining $200,000 installments.
- The exact default provisions and remedies in the Settlement Agreement.
- The current status, ownership, restrictions, and potential market impact of the 60,000 retained shares.
- Any subsequent filings reporting payment, amendment, settlement completion, or additional obligations.